Oxford vaccine called 'Covishield' in India, likely to hit market in 2021
With the trials of the SII’s COVID-19 vaccine being developed by AstraZeneca and Oxford University showing encouraging results, Indian manufacturers Serum Institute of India said that the important phase-3 of the trials will start win August and already 5,000 volunteered themselves for the trial in India.
After the Oxford-AstraZeneca vaccine candidate appeared to be safe in the first and second phases of human trials in the UK, Indian manufacturer of the vaccine Serum Institute of India (SII) today said the decisive third phase of the trials would start in India from August.
According to Serum institute Chairman Dr. Cyrus Poonawalla, the SII was committed to manufacture at least one billion doses of the University of Oxford’s COVID-19 vaccine after getting required approvals.
The Oxford-AstraZeneca vaccine candidate will be called Covishield in India and is likely hit the market in early 2021, SII said.
Dr. Poonawalla said: “We [the SII] have come at a stage where chances of failure [of the Oxford vaccine project] look remote as we are spending more than $100 million for this facility. If we get the approvals and trials are completed successfully to ensure a safe and efficacious vaccine, then lots of companies will manufacture it and India will be the largest producer of the COVID vaccine in the world.”
With the trials of the SII’s COVID-19 vaccine being developed by AstraZeneca and Oxford University showing encouraging results, SII CEO Adar Poonawalla had earlier said at least 300 million doses of ‘Covishield’ would be ready by December this year.
According to a report by the NDTV, the vaccine will cost less than 1,000 INR per dose and as for the trials, more than 5,000 people have enrolled themselves for clinical trials of the Oxford vaccine to be conducted in India.